Literature DB >> 1906610

Misoprostol does not alter the pharmacokinetics of propranolol.

P N Bennett1, G C Fenn, L J Notarianni, C E Lee.   

Abstract

Twelve healthy volunteers took part in a randomised, double-blind, balanced, cross-over study to investigate the effect of misoprostol on the pharmacokinetics of propranolol. The subjects took propranolol 80 mg twice daily by mouth plus either misoprostol 400 micrograms twice daily or placebo by mouth for 14.5 days, followed by a 2-week washout period, followed by the alternate treatment for 14.5 days. Misoprostol had no significant effect on the t/2, Cmax or AUC of propranolol either after a single dose or at steady state.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906610      PMCID: PMC2398868          DOI: 10.1136/pgmj.67.787.455

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  5 in total

Review 1.  Misoprostol: discovery, development, and clinical applications.

Authors:  P W Collins
Journal:  Med Res Rev       Date:  1990 Apr-Jun       Impact factor: 12.944

2.  Potential drug interactions with misoprostol: effects on the pharmacokinetics of antipyrine and propranolol.

Authors:  P N Bennett; G C Fenn; L J Notarianni
Journal:  Postgrad Med J       Date:  1988       Impact factor: 2.401

3.  Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.

Authors:  R R Shah; N S Oates; J R Idle; R L Smith; J D Lockhart
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30

4.  Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.

Authors:  M Danhof; E de Groot-van der Vis; D D Breimer
Journal:  Pharmacology       Date:  1979       Impact factor: 2.547

5.  Metabolism and pharmacokinetic studies of misoprostol.

Authors:  G Schoenhard; J Oppermann; F E Kohn
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

  5 in total
  2 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 2.  Pharmacokinetic drug interactions with anti-ulcer drugs.

Authors:  R D Negro
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.